Shanghai MicroPort MedBot (Group) Co., Ltd. Class H ( (HK:2252) ) has issued an update.
Shanghai MicroPort MedBot reported a significant revenue increase of 146% for the year ended December 31, 2024, reaching RMB257.2 million, driven by strong sales growth in domestic and overseas markets. Despite a net loss of RMB647.1 million, the company improved its financial performance by reducing its net loss by 36.8% compared to the previous year, attributed to increased gross profit, reduced R&D costs, and decreased administrative expenses. The company also successfully reduced its net free cash outflow by 42%, reflecting strategic focus and efficiency measures, although these gains were partially offset by an impairment loss on an overseas investment.
More about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. is a company incorporated in the People’s Republic of China, focusing on the medical technology industry. It specializes in developing and manufacturing medical robotics and related technologies, with a market focus on both domestic and international sales.
YTD Price Performance: 88.01%
Average Trading Volume: 13,365,258
Technical Sentiment Signal: Sell
Current Market Cap: HK$17.99B
See more data about 2252 stock on TipRanks’ Stock Analysis page.